A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
Active, not recruiting · Phase 2 · NCT06365853
Conditions: Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive
At a glance
- Research payments reported, 2025
- $320,889
- U.S. investigators named
- 12
- Sites paid
- 12
- Planned or actual enrollment
- 108
About the trial
- Sponsor
- AbbVie
- Tested
- Mirvetuximab Soravtansine (drug), Lubricating Eye Drops (drug), Prednisolone acetate ophthalmic suspension 1% eye drops (drug), Brimonidine tartrate ophthalmic solution eye drops (drug)
- Dates
- Started 2024-07-29; completion 2027-02
- Results posted
- Not yet
The purpose of this study is to evaluate the incidence rate and severity of prespecified mirvetuximab soravtansine (MIRV)-related ocular treatment-emergent adverse events (TEAEs) and assess prophylaxis strategies in all participants (symptomatic and asymptomatic) undergoing prospective ophthalmic evaluation with recurrent ovarian cancer (participants with either platinum-sensitive ovarian cancer \[PSOC\] or platinum-resistant ovarian cancer \[PROC\]) with high folate receptor alpha (FRα) expression.
From ClinicalTrials.gov, last updated 2026-08-21. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $320,889 in research payments for this study in 2025 (27 payments).
Products named: Elahere
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Dana M. Chase, M.D. Gynecologic Oncology · Los Angeles, CA
- Lindsay Brubaker, M.D. Gynecologic Oncology · Aurora, CO
- Mary E. Gordinier, M.D. Gynecologic Oncology · Louisville, KY
- Tashanna K. Myers, MD Gynecologic Oncology · Springfield, MA
- James F. Barter, M.D. Gynecologic Oncology · Rockville, MD
- Clarissa Polen-de, MD Gynecologic Oncology · Rochester, MN
- Erica Huelsmann, MD Gynecologic Oncology · Saint Louis, MO
- Angeles A. Secord, MD Gynecologic Oncology · Durham, NC
- Joyce N. Barlin, M.D. Gynecologic Oncology · Albany, NY
- Jason D. Wright, M.D. Gynecologic Oncology · New York, NY
- Jayanthi S. Lea, MD Gynecologic Oncology · Dallas, TX
- Joseph A. Lucci, MD Gynecologic Oncology · Galveston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Duke University $55,127
- The University of Texas Southwestern Medical Center $51,924
- Ronald Reagan UCLA Medical Center, CA $44,570
- The Regents of the University of Colorado $30,150
- Baystate Medical Center, MA $25,695
- Womens Cancer Care Associates LLC $23,981
- The Trustees of Columbia University in The City of New York $22,386
- Mercy Research $20,000
- Summa Health $13,640
- The University of Texas Health Science Center at Houston $12,025
- Norton Healthcare Inc $11,792
- Holy Cross Hospital, MD $9,599
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.